Our award-winning reporting has moved

Context provides news and analysis on three of the world’s most critical issues:

climate change, the impact of technology on society, and inclusive economies.

INTERVIEW - What it would take to get super-cold COVID-19 vaccine to West Africa

by Nellie Peyton | @nelliepeyton | Thomson Reuters Foundation
Thursday, 12 November 2020 18:47 GMT

A health worker holds a COVID-19 sample collection kit of a vaccine trials' volunteer, after they were tested for the coronavirus disease and take part in the country's human clinical trial for potential vaccines at the Wits RHI Shandukani Research Centre in Johannesburg, South Africa, August 27, 2020. REUTERS/Siphiwe Sibeko

Image Caption and Rights Information

A promising new coronavirus vaccine must be kept at Antarctic temperatures, raising concerns for delivery in Africa

By Nellie Peyton

DAKAR, Nov 12 (Thomson Reuters Foundation) - Hope is rising that a new vaccine could halt the COVID-19 pandemic - for some - but lessons learnt from past vaccine programmes in West Africa suggest millions more might miss out.

The super-cold storage temperature required for the new vaccine will make it near impossible to deliver in rural parts of Africa, said public health expert Evelyn Castle.

"We would need all new infrastructure," said Castle, executive director of the Nigeria-based non-profit organisation eHealth Africa, which in 2016 helped distribute an Ebola vaccine in Sierra Leone at similar temperatures.

"(In Sierra Leone), we had to do full renovations of some of the facilities we worked in."

The pharmaceutical company Pfizer and its partner BioNTech SE said on Monday that initial trials showed their experimental COVID-19 vaccine was more than 90% effective.

But the vaccine must be kept at temperatures of minus 70 degrees Celsius (-94 F) or below - colder than the North Pole. Even sophisticated U.S. hospitals say they lack that capability.

Routine vaccines typically need to be stored at 2-8°C, about the temperature of a normal refrigerator, and even this is a challenge for much of West Africa, where electricity is non-existent or unreliable, said Castle.

The Ebola vaccine trial in Sierra Leone involved immunising about 8,000 health workers - quite a task, but nothing compared to the job of protecting millions against COVID-19, said Castle.

Coronavirus has killed almost 1.3 million people worldwide and infected 50 million. European nations have already started making deals with Pfizer to purchase millions of doses of the vaccine.

Other companies including Moderna Inc , Johnson & Johnson and Novavax Inc are working on developing vaccines that would not need such low temperatures.

But the first out the block, if it wins emergency U.S. approval as hoped this month, would be Pfizer's, ensuring a global scramble for infrastructure to make it work.


In Nigeria, many rural health centres have solar-powered fridges, but Castle said they lack the power to hit -70°C.

Generators would be needed, along with someone to ensure they were serviced, fuelled, and monitored constantly so they didn't drop below the temperature threshold, she said.

Transportation would also be challenging, and not just because of temperature constraints.

"Obviously there are a lot of challenges with keeping it cold in transport, but you might not even have cars, you might not have fuel, you might not have drivers to do the actual delivery," she said.

In Sierra Leone, health centres had to be equipped with running water so the Ebola vaccine could be administered safely, and with internet to keep track of patient records.

Given all this, a likely scenario is that any vaccine would go to urban areas first, Castle said - in itself a potential problem.

"If we have a limited number of vaccines, who are we going to target? Are we really just going to be giving this to the rich people living in cities?"

Related stories:

Pfizer vaccine brings little cheer to coronavirus-hit India

Can vaccines reach the world's poorest? 

Who owns the virus? Pandemic sparks debate on data sharing

(Reporting by Nellie Peyton, editing by Lyndsay Griffiths; Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers the lives of people around the world who struggle to live freely or fairly. Visit http://news.trust.org)

Our Standards: The Thomson Reuters Trust Principles.